论文部分内容阅读
目的观察唑来膦酸联合NP化疗对乳腺癌骨转移的干预效果及安全性影响。方法选取2014年2月—2015年3月驻马店市第一人民医院肿瘤外科收治的86例乳腺癌患者为研究对象,随机数字表法均分为观察组和对照组,对照组给予唑来膦酸治疗,观察组在对照组基础上联合NP化疗治疗,两组均持续治疗2个月,观察两组治疗前、后骨代谢指标[I型前胶原氨基肽(PINP)、β-胶原特殊系列(β-CTx)、骨钙素(OC)、骨特异性碱性磷酸酶(BAP)]变化及治疗后两组生活质量改善情况及不良反应发生情况。结果治疗后观察组PINP、OC、BAP分别均较治疗前显著升高,β-CTx较治疗前显著降低,且治疗后观察组PINP(95.70±7.29)μg/L、OC(12.41±1.20)μg/L、BAP(6.74±0.63)μg/L分别均较对照组升高显著,β-CTx(1.17±0.12)μg/L较对照组降低显著,均具有统计学意义(P<0.05);治疗后观察组生活质量总改善率86.05%较对照组67.44%显著高(P<0.05);观察组不良反应总发生率16.28%较对照组13.95低,差异不显著(P>0.05)。结论唑来膦酸联合NP化疗对乳腺癌骨转移干预效果显著,可显著改善患者生活质量,两者联合应用毒副作用患者可耐受,是一种安全可靠的治疗方案。
Objective To observe the intervention effect and safety of zoledronic acid combined with NP chemotherapy on bone metastasis of breast cancer. Methods Totally 86 breast cancer patients treated in the Department of Oncology, First People’s Hospital of Zhumadian City from February 2014 to March 2015 were selected as the research object. The random number table was divided into observation group and control group. The control group was given zoledronic acid The treatment group and the observation group were treated with NP chemotherapy on the basis of the control group. Both groups were treated for 2 months. The indexes of bone metabolism (such as PINP, β-collagen special series β-CTx), osteocalcin (OC) and bone specific alkaline phosphatase (BAP), and the improvement of quality of life and incidence of adverse reactions in the two groups after treatment. Results After treatment, the levels of PINP, OC and BAP in the observation group were significantly higher than those before treatment, and the levels of β-CTx in the observation group were significantly lower than those before treatment (P <0.01) /L,BAP(6.74 ± 0.63) μg / L, respectively, compared with the control group increased significantly, β-CTx (1.17 ± 0.12) μg / L decreased significantly compared with the control group, were statistically significant (P <0.05) The total improvement rate of quality of life in observation group was 86.05%, which was significantly higher than 67.44% in control group (P <0.05). The total incidence of adverse reactions in observation group was 16.28% lower than that in control group (13.95), with no significant difference (P> 0.05). Conclusion Zoledronic acid combined with NP chemotherapy has significant effect on bone metastasis of breast cancer, which can significantly improve the quality of life of patients. Both of them are tolerable in patients with toxic side effects, which is a safe and reliable treatment plan.